Mounjaro KwikPen 10 — Tirzepatide 10 mg, 1 pcs, Eli Lilly

Mounjaro KwikPen 10 — Tirzepatide 10 mg (1 Pen / 4 Doses) Cold chain · Storage +2…+8 °C

Product code: 361

19372₴ 20651₴ -6%

Dosage

1

Needles are not included

The pen comes without needles — they are sold separately.

Number of needles
4
Cold chain Storage +2…+8 °C

This medicine requires temperature control. We pack it in a thermal box with cold packs for safe delivery.

Please return the thermal box with cold packs after delivery. An additional charge applies only if you wish to keep the box.

How to check the medicine on delivery

The pens arrive in the original factory packaging with intact seals, and we strictly follow the storage conditions. When you open the box, do the standard check from the Eli Lilly instructions: hold the pen up to the light and look through the clear window. The solution should be clear, colourless or slightly yellow, with no cloudiness or particles. We ask every customer to do this check straight away, so you can start the course with complete peace of mind.

Active ingredient
Storage temperature
Cold chain · Storage +2…+8 °C

Shipped in a thermal box with cold packs

Dosage form Solution for subcutaneous injection in a pen injector
Volume 0.6 ml
Units per pack 1
Packaging Pen injector in a carton box

Mounjaro 10 mg KwikPen is a first-in-class, novel pharmaceutical preparation containing Tirzepatide. It represents the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Mounjaro is indicated for the treatment of type 2 diabetes mellitus and for chronic weight management in adults with obesity or overweight. By simultaneously targeting both GIP and GLP-1 receptors, Tirzepatide enhances glucose-dependent insulin secretion, improves insulin sensitivity, delays gastric emptying, and acts on central brain pathways to significantly reduce appetite and body weight.

Manufacturer: Eli Lilly and Company (USA). A global leader in biopharmaceuticals and metabolic healthcare, renowned for strict manufacturing standards, extensive clinical trial programs, and pioneering innovations in diabetes and endocrinology care.

⚠️ Important Commercial & Packaging Notice: Mounjaro is supplied in a pre-filled, multi-dose Mounjaro KwikPen 10 mg device containing a total volume of 2.4 ml. Each KwikPen device delivers exactly 4 doses of 10 mg (one weekly subcutaneous injection for a 4-week treatment course). The 10 mg strength serves as an important titration milestone when stepping up from the 7.5 mg dose, or as an individualized long-term maintenance dose.

Key Clinical Advantages and Features of Mounjaro 10 mg KwikPen:

  • ✅ Dual Receptor Agonism (GIP/GLP-1): Delivers synergistic metabolic benefits, achieving superior glycemic control and weight reduction compared to selective GLP-1 receptor mono-agonists.
  • ✅ High Clinical Potency: The 10 mg dosage demonstrates outstanding efficacy in clinical trials, driving significant weight reduction and HbA1c normalization while maintaining optimal patient tolerability.
  • ✅ User-Friendly KwikPen System: Multi-dose pen designed for convenient, once-weekly subcutaneous administration, providing a complete 4-week treatment regimen per pen.
  • ✅ Cardiometabolic Optimization: Positively impacts cardiometabolic risk factors, including blood pressure, lipid profiles, and intrahepatic fat accumulation.

Mounjaro 10 mg KwikPen is supplied as a clear, colorless to slightly yellow solution for subcutaneous injection in a pre-filled multi-dose KwikPen injector:

  • Packaging Configuration: 1 pre-filled multi-dose KwikPen containing 2.4 ml of solution (delivering 4 doses).
  • Active Ingredient: Tirzepatide — 10 mg per single dose. Total active drug content per pen is 40 mg.
  • Inactive Excipients: Sodium phosphate dibasic heptahydrate, sodium chloride, benzyl alcohol (preservative), water for injections, sodium hydroxide and/or hydrochloric acid (for pH adjustment).

Pharmacodynamics: Tirzepatide is a 39-amino-acid synthetic peptide engineered with a C20 fatty diacid moiety that enables non-covalent binding to human albumin, extending its half-life to approximately 5 days. Tirzepatide binds to and activates both GIP and GLP-1 receptors. Simultaneous activation stimulates glucose-dependent insulin secretion, suppresses glucagon release, lowers fasting and postprandial glucose levels, slows gastric emptying, and acts on hypothalamic feeding centers to increase satiety and reduce caloric intake.

Pharmacokinetics: Following subcutaneous administration, maximum plasma concentration (Cmax) is attained within 8 to 72 hours. Absolute bioavailability is approximately 80%. Steady-state plasma concentrations are achieved following 4 weeks of once-weekly administration. Tirzepatide is metabolized via proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid side chain. The terminal elimination half-life (T1/2) is approximately 5 days (120 hours), supporting once-weekly dosing. Elimination occurs via urine and feces as metabolic fragments.

Mounjaro 10 mg KwikPen is indicated for adult patients in the following therapeutic areas:

  • 🔹 Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, either as monotherapy (when metformin is inappropriate) or in combination with other antihyperglycemic agents (metformin, sulfonylureas, SGLT-2 inhibitors, insulin).
  • 🔹 Chronic Weight Management: As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m² (obesity) or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).

Mounjaro 10 mg KwikPen is formulated strictly for subcutaneous injection:

  • 💊 Dose Escalation Schedule: Therapy must be initiated at 2.5 mg once weekly for 4 weeks. After 4 weeks, increase the dose in 2.5 mg increments every 4 weeks (2.5 mg ➔ 5 mg ➔ 7.5 mg ➔ 10 mg ➔ 12.5 mg ➔ 15 mg). Escalation to the 10 mg dose should only occur after completing at least 4 weeks of treatment on the 7.5 mg dose.
  • ⏱️ Administration Schedule: Administer once weekly, on the same day each week, at any time of day, with or without food. Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites with each weekly dose.
  • 💉 KwikPen Operation: The multi-dose KwikPen is pre-configured to deliver a fixed 10 mg Tirzepatide dose per injection. Attach a new sterile pen needle before each administration.
  • 🚫 Missed Dose Management: If a dose is missed, administer it as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have elapsed, skip the missed dose and resume the regular weekly schedule on the next planned day.

Mounjaro KwikPen is a multi-dose pen: it holds 4 fixed doses of 10 mg, one per week. The steps below follow the official Eli Lilly instructions. Needles are not included: you need KwikPen-compatible pen needles — a new one for every injection.

1. Injection schedule

  • Once a week, on the same day of the week. Time of day and meals do not matter.
  • To change the day, make sure at least 3 days (72 hours) pass between two injections.
  • Missed a dose? Inject as soon as possible if no more than 4 days (96 hours) have passed. If more, skip that dose and take the next one on your usual day. Never take two doses at once.

2. Where to inject

The medicine is injected under the skin:

  • stomach (abdomen) — at least 5 cm from the belly button;
  • front of the thigh;
  • back of the upper arm — only if another person gives the injection.

Change the injection site every week: you can use the same area, but pick a different spot.

3. How to inject

  1. Get ready. Wash your hands with soap and water. Taking the pen out of the fridge 15–30 minutes before helps: room-temperature solution is more comfortable to inject.
  2. Check the pen. Pull off the cap. Make sure the label shows your dose, the pen is not expired or damaged, and the solution is clear, colourless to slightly yellow, without cloudiness or particles. Do not use a pen that has been frozen.
  3. Wipe the red rubber seal at the end of the pen with an alcohol swab.
  4. Attach a new needle. Pull the paper tab off the needle, push it straight onto the pen and twist until tight. Pull off the large outer needle shield (keep it — you will need it) and the small inner shield (throw it away).
  5. Prime the pen — before every injection. Slowly turn the dose knob until you hear 2 clicks and the extended line appears in the dose window — this is the prime position. Hold the pen needle up and tap the cartridge gently so air bubbles rise. Push the dose knob in until it stops and slowly count to 5 while holding it. A drop of medicine should appear at the needle tip.
    No drop — repeat priming up to 2 more times; still nothing — change the needle and try 1 more time. Do not prime more than needed: the pen holds enough for 4 doses, and you may lose the last one.
  6. Dial the dose. Turn the dose knob until it stops — the full-dose icon (0.6 ml) appears in the window. The dose is fixed, there is nothing to adjust. The marks on the pen body are not dose indicators.
  7. Inject. Insert the needle into the skin. Push the dose knob in until it stops and slowly count to 5 while holding it. Only then remove the needle.
  8. Check the dose window. If the starting icon is back, you have received the full dose. A drop on the needle tip is normal. If the icon is not there, insert the needle again and finish pushing the knob. Do not redial and do not repeat the injection.
  9. If you see blood, press lightly with gauze or a cotton ball. Do not rub.
  10. Remove the needle. Carefully put the outer shield back on, unscrew the needle and drop it into a sharps container (a thick plastic bottle will do). Do not store the pen with a needle attached: it may leak or the needle may block.
  11. Put the pen cap back on.

4. Storage

  • New pens — in the fridge at +2…+8 °C until the expiry date. Do not freeze.
  • Pen in use — at room temperature up to +30 °C, away from heat, always with the cap on.
  • Throw the pen away after 4 doses or 30 days after first use, whichever comes first, even if some solution is left. Do not inject the leftover.
  • Never share your pen, even with a new needle.

5. How the dose is increased

Treatment starts with 2.5 mg once a week for 4 weeks — a starting dose to get used to the medicine, not a treatment dose. After that the doctor raises the dose by 2.5 mg no more often than every 4 weeks (5 → 7.5 → 10 → 12.5 → 15 mg). One pen lasts exactly 4 weeks. Only your doctor should change the dose.

This is a short summary. Read the leaflet in the box before your first injection.

Mounjaro 10 mg KwikPen is strictly contraindicated in patients presenting with:

  • ❌ Hypersensitivity to Tirzepatide or to any of the inactive excipients in the formulation.
  • ❌ Personal or family history of Medullary Thyroid Carcinoma (MTC).
  • ❌ Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • ❌ Type 1 diabetes mellitus or treatment of diabetic ketoacidosis.
  • ❌ Severe gastrointestinal disease, including severe gastroparesis.
  • ❌ Pregnancy and breastfeeding.
  • ❌ Pediatric patients under 18 years of age (safety and efficacy not established).

Consider the following interactions when administering Mounjaro 10 mg KwikPen:

  • ⚠️ Insulin and Insulin Secretagogues (Sulfonylureas): Co-administration increases the risk of hypoglycemia. A dose reduction of insulin or sulfonylurea may be required.
  • ⚠️ Oral Medications: Mounjaro causes a delay in gastric emptying, which may impact the rate and extent of absorption of concomitantly administered oral medications (e.g., oral contraceptives, antibiotics, narrow therapeutic index drugs). Patients taking oral contraceptives should switch to a non-oral method or add a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation.

Mounjaro 10 mg KwikPen is **contraindicated during pregnancy**. Animal reproduction studies have shown potential embryofetal toxicity. Women of childbearing potential should use effective contraception during treatment. Discontinue Mounjaro at least 2 months prior to a planned pregnancy. It is unknown whether Tirzepatide is excreted in human milk; breastfeeding should be discontinued during treatment.

Mounjaro 10 mg KwikPen at the 10 mg dose may cause adverse reactions, most commonly involving the gastrointestinal tract, which typically subside over time:

  • 🤢 Gastrointestinal (Very Common): Nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, flatulence, gastroesophageal reflux disease.
  • 💆 General Disorders: Fatigue, asthenia, dizziness, injection site reactions (erythema, pruritus, hematoma).
  • 📉 Metabolic & Laboratory: Hypoglycemia (when used with insulin or sulfonylureas), decreased appetite, elevated serum lipase/amylase.
  • ⚠️ Rare but Serious Events: Acute pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury (secondary to dehydration from GI adverse reactions), severe hypersensitivity reactions (anaphylaxis, angioedema).

Overdose Symptoms: Massive overdosage of Tirzepatide may lead to severe gastrointestinal distress (severe nausea, persistent vomiting, diarrhea) and significant hypoglycemia, particularly if co-administered with other antidiabetic agents.

Overdose Management: Provide supportive medical treatment according to clinical symptoms. Monitor blood glucose levels closely and maintain adequate fluid and electrolyte balance. No specific antidote exists.

Storage instructions for Mounjaro 10 mg KwikPen:

  • ❄️ Unopened Pens: Store refrigerated between 2 °C to 8 °C. Do not freeze! Discard if the device has been frozen.
  • 🌡️ In-Use / Room Temperature Storage: An in-use or unopened pen may be stored at room temperature up to 30 °C for a maximum period of 30 days. Discard the pen after 30 days, even if medication remains inside.
  • 💧 Light Protection: Store in the original outer carton to protect from direct light. Keep the cap on the pen when not in use.
  • 👶 Safety Precautions: Keep out of reach and sight of children. Store the pen without a needle attached.

To ensure the authenticity of your Mounjaro 10 mg KwikPen device, check for the following anti-counterfeiting security features:

  • 🛡️ Packaging Design: The original carton features crisp graphics with a distinct magenta/pink corner accent block, prominent Mounjaro® and KwikPen® trademarks, and official Lilly branding. The front panel explicitly indicates "10 mg" and "Once weekly".
  • 🔍 Batch and Expiry Markings: The side panel of the carton and the pen label display deeply stamped or thermal-printed Lot Number (LOT) and Expiration Date (EXP), which must be identical.
  • 📦 KwikPen Build Quality: The authentic device consists of a sturdy grey body with a purple cap and magenta dose accents matching the official 10 mg color code. The dose window clearly displays fixed unit indicators. The liquid solution inside the glass cartridge must be completely clear, colorless to light yellow, and free of visible particles.
100% original product
Delivery across Ukraine
1

Needles are not included

The pen comes without needles — they are sold separately.

Number of needles
4

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 06.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00